StreetInsider.com News Articles

Form 10-Q Equillium, Inc. For: Jun 30

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921364.html

Form 10-Q Equillium, Inc. For: Jun 30

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921364.html

Form SCHEDULE 13G Equillium, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921181.html

Form SCHEDULE 13G Equillium, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921181.html

Form 8-K Equillium, Inc. For: Aug 13

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921088.html

Form 8-K Equillium, Inc. For: Aug 13

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921088.html

Equillium, Inc. (EQ) Tops Q2 EPS by 1c

Thu, 13 Aug 2026 16:06:17 -0400

Equillium, Inc. (NASDAQ: EQ) reported Q2 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05).

For earnings history and earnings-related data on Equillium, Inc. (EQ) click here.

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update highlighting continued progress in support of EQ504, its potent and

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

Form SCHEDULE 13G/A Equillium, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26911282.html

Form SCHEDULE 13G/A Equillium, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26911282.html

Clear Street Starts Equillium (EQ) at Buy

Tue, 21 Jul 2026 16:17:57 -0400

Clear Street analyst Kaveri Pohlman initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $9.00.

The analyst comments "We initiate coverage of EQ with a Buy rating and a $9 PT. We believe lead asset EQ504, an oral AhR agonist, offers an attractive risk-reward profile in IBD, with a UC P1 trial set to initiate in 3Q26 and data expected in 1H27. EQ504 combines biologically validated mechanism, colon-targeted delivery to enhance safety, and once-daily oral convenience. EQ504 has the potential to break the current efficacy ceiling, supported by its pleiotropic biology, which overlaps with obefazimod’s

Clear Street Starts Equillium (EQ) at Buy

Tue, 21 Jul 2026 16:17:57 -0400

Clear Street analyst Kaveri Pohlman initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $9.00.

Piper Sandler Starts Equillium (EQ) at Overweight

Mon, 13 Jul 2026 04:02:18 -0400

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ: EQ) with a Overweight rating and a price target of $20.00.

The analyst comments: “We are initiating coverage on Equillium, Inc. (EQ) with an OW rating and $20 PT, where we believe EQ is significantly undervalued compared to competitors within the UC space. Notably, their lead asset is EQ504, an AhR modulator clinically validated by indigo naturalis and obefazimod yet instilled with potential for higher potency and differentiated colontargeted engagement for cleaner safety. Accordingly, we review this depth of data from 4 studies of AhR modulators and obefazimod which collectively rationalize

Piper Sandler Starts Equillium (EQ) at Overweight

Mon, 13 Jul 2026 04:02:18 -0400

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ: EQ) with a Overweight rating and a price target of $20.00.

Oppenheimer Reiterates Outperform Rating on Equillium (EQ)

Tue, 30 Jun 2026 06:42:54 -0400

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $7.00 price target on Equillium (NASDAQ: EQ).

The analyst commented: "We see last night's positive maintenance data reveal from Abivax in ulcerative colitis (UC) as supportive for EQ504. Obefazimod's (obe's) impressive efficacy in refractory Phase 3 subsets, as achieved through treatment continuation and/or dose escalation, adds validation for EQ's more potent immunomodulator as it enters UC clinical development. While we regarded malignancy concerns as triggered by ABVX's recent disclosure as obe-specific given cumulative AhR modulator experience, last night's more mature safety update should nonetheless assuage any investor worry here re EQ504. Reiterate

Form 144 Equillium, Inc. Filed by: Connelly Stephen

Fri, 05 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260605/26612123.html

Form 144 Equillium, Inc. Filed by: Connelly Stephen

Fri, 05 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260605/26612123.html

Form 4 Equillium, Inc. For: Jun 05 Filed by: Zedelmayer Christine

Fri, 05 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26611827.html

Form 4 Equillium, Inc. For: Jun 05 Filed by: Zedelmayer Christine

Fri, 05 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26611827.html

Form 4 Equillium, Inc. For: Jun 04 Filed by: Connelly Stephen

Fri, 05 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260605/26611820.html

Form 4 Equillium, Inc. For: Jun 04 Filed by: Connelly Stephen

Fri, 05 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260605/26611820.html

Form 144 Equillium, Inc. Filed by: Connelly Stephen

Thu, 04 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260604/26606932.html